What happens Globalist-Communist science embraces monetary gain at the expense of the actual public good? YOU GET a Chi-Ná Wuhan COVID-19 virus infecting the world for Communist gain and Globalist power. Consider Part 1 and 2 of the Canada Free Press articles “Pandemic, Plandemic, or Both?”
Your generosity is always appreciated – various credit, check
& debit cards are accepted by my PayPal account:
Or support by getting in the Coffee from home business –
OR just buy some FEEL GOOD coffee, that includes immune boosting products.
Pandemic, Plandemic, or Both? PT One
By Lee Cary
May 22, 2020
Somewhere along the way, two-thirds of America’s foundational trilogy of “Life, Liberty, and the Pursuit of Happiness” abdicated to the first third. So what happened?
SARS-CoV-2, also known as the 2019 novel coronavirus, was shortened to COVID-19. Or, to be politically incorrect, the Wuhan Virus or China Virus. And, for the very bold, the CCP (Chinese Communist Party) Virus. SARS means “Severe Acute Respiratory Syndrome”.
SARS-CoV-1 was identified in 2003. The search for a vaccine has been underway for 17 years. SARS-CoV-1 is thought to have, perhaps, originated in bats. Perhaps, spread to cats. But surely, first infected humans in the Guangdong province of southern China in 2002.
SARS-CoV-2 is thought, maybe, to have a similar bat pedigree, but with a different point of Chinese entry that spread globally. Whether it was created in a lab, or in nature, is debated.
The Guardians of Public Health
The Centers for Disease Control and Prevention (CDC) “works 24/7 to protect America from health, safety and security threats, both foreign and in the U.S.” It opened on July 1, 1946 with 400 employees. In 2018, Forbes reported it had 10,639 “staffers”.
The National Institutes of Health (NIH), founded in the late 1880s, is “the primary agency of the United States government responsible for biomedical and public health research”. In 2012, the NIH had 20,262 employees. More current numbers are unreported. Dr. Tony Fauci, age 79, has directed the NIH Institute of Allergy and Infectious Diseases since 1984.
The Private Lab: Gilead Sciences
Snapshot: “Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.”
Gilead News Highlights:
August 2, 2012 – “Gilead Sciences inks deals with 3 Indian companies including Ranbaxy Laboratories for low-cost HIV drug” Then, nine months later…
May 13, 2013 – “Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay $500 Million to Resolve False Claims Allegations, cGMP Violations and False Statements to the FDA”
“Ranbaxy USA pleaded guilty to three felony FDCA [Food, Drug, and Cosmetic Act] counts, and four felony counts of knowingly making material false statements to the FDA [Food and Drug Administration]. The generic drugs at issue were manufactured at Ranbaxy’s facilities in Paonta Sahib and Dewas, India…[T]he whistleblower, Dinesh Thakur, a former Ranbaxy executive, will receive approximately $48.6 million from the federal share of the settlement amount. The case is U.S. ex rel. Thakur v. Ranbaxy Laboratories Limited, Case No. JFM-07-962 (D. Md.)”
Also reported, “FDA inspectors found tablets with a ‘black fibre’ suspected to be human hair and pills with apparent machinery oil ‘black spots’ at the Mohali plant. Last year, glass was detected in some pills.”
On behalf of Gilead, Ranbaxy Labs cooked-up gnarly drugs.
August 4, 2014 – Two Gilead employees bring accusations against their employer in UNITED STATES OF AMERICA, ex. rel. CAMPIE et al., Plaintiffs, v. GILEAD SCIENCES, INC., et al., Defendants.
Jeffery Campie was Gilead’s Senior Director of Commercial Quality Assurance, and his wife Sherilyn Campie was an Associate Manager of Quality Control for Gilead.
The two claimed that Gilead had committed “violations of the False Claims Act (“FCA”), 31 U.S.C. § 3729, et. seq., and analogous state statutes and city ordinances, claiming that Gilead defrauded the federal, state, and local governments by selling billions of dollars’ worth of nonconforming drugs, which were paid for through programs like Medicare, Medicaid, and the President’s Emergency Plan for AIDS Relief [AKA: PEPFAR]”.
The pair stated that “…Gilead develops, manufactures, and sells drugs used to treat diseases like HIV/AIDS, hepatitis, and cystic fibrosis. Gilead manufactured and distributed drug products that failed to meet applicable specifications because they (1) were contaminated with a host of adulterants, including, but not limited to, arsenic, cadmium, mercury, lead, nickel, steel, titanium, chromium, iron, cobalt, aluminum, metal shards, glass, rubber, polyethylene (plastic), stones or pebbles, cement, paint, wood fibers and fibrous building materials, organic material, microbes (including bacillus cereus), paper, Teflon, acetaminophen, other degradants, and blood; (2) were improperly manufactured using active pharmaceutical ingredients (“API”) [the part of any drug that produces the intended effects] sourced on the cheap from unregistered facilities in China and otherwise in violation of federal law and Good Manufacturing Practices; (3) were subjected to extreme storage and shipping conditions; and (4) lacked proper testing and analysis…These nonconforming drugs were paid for by the government through programs like Medicare, Medicaid and the President’s Emergency Plan for AIDS Relief.”
November 6, 2019 – “United States Files Patent Infringement Lawsuit Against Gilead Related to Truvada and Descovy for Pre-exposure Prophylaxis of HIV.”
“In the complaint, HHS [U.S. Department of Health and Human Services] alleges that Gilead has willfully and deliberatively induced infringement of the HHS patents. The complaint further alleges that, as a result of such infringement, Gilead has profited from research funded by hundreds of millions of taxpayer dollars and reaped billions from PrEP [Pre-exposure prophylaxis when people at risk for HIV take daily medicine to prevent HIV] through the sale of Truvada and Descovy.”
In short, the U.S. Government (USG) claims that Gilead infringed upon USG patents by creating drugs that Gilead sold without rendering payment due to the USG for use of its patents. Furthermore, Gilead then sold some of those drugs to the USG. I.e., a kind of double-dipping, or maybe straight theft.
Gilead Recycles Remdesivir
Gilead Sciences is the biopharmaceutical company that today markets Remdesivir. It’s the drug selected, by the government doctors in the white lab coats, to mitigate the symptoms of SARS-CoV-2. It was originally developed to treat Hepatitis C. When it was tested against the Ebola and Marburg virus diseases, it failed to work.
When SARS-CoV-2 came along, Remdesivir was taken off the shelf and used against SARS-CoV-2—not as a cure, but as a stopgap drug to mitigate symptoms. Hence, the Mayor of Los Angeles awaits a vaccine.
So, was all this the birth of a pandemic, born of a plandemic, or a child of both?
To be continued in Part 2 of “Pandemic, Plandemic, or Both?”
Pandemic, Plandemic, or Both? (Part 2)
By Lee Cary
May 23, 2020
Review of Part 1 Takeaways
- When political correctness is put aside, SARS-CoV-2 is Covid-19’s real name.
- The combined staff of the CDC and the NIH is, at last count, about 31,000.
- The American pharmaceutical company most engaged in the SARS-CoV-2 episode, Gilead Sciences, has a dodgy history, and is being sued by the U.S. Government for patent infringement.
- Gilead’s drug, Remdesivir, being pushed hard by the federal government’s medical establishment, is a failed effort left over from the search for a hepatitis C drug.
First U.S. SARS-CoV-2 case used Remdesivir on/about January 27
Two articles recount the ordeal of America’s first patient to struggle with the virus.
One is out of Spokane, Washington. The other, dated February 17, 2020, is from the South China Morning Post, out of Hong Kong, China.
The Post states that the 35-year-old patient flew into the Seattle-Tacoma International Airport on January 15 after visiting relatives in Wuhan, China. Few other details are reported in the Post.
Here’s how a Spokane paper heralded the story: Spokane Spokesman, January 31, 2020, “Washington state coronavirus patient treated with investigational, unapproved Ebola drug”.
The unnamed male patient was admitted to Providence Regional Medical Center in Everett, WA on January 20.
Although Remdesivir was not approved for use by the Food and Drug Administration, it was available if recommended by a physician for “compassionate use”.
After the drug was administered with patient approval, Dr. Jay Cook, Chief Medical Officer at Providence, said, “To my knowledge this is the first reported case in the world where this drug has been used in a human application against this virus”.
Sometime between January 31 – February 3, the patient was released from the hospital. No other details are available to the public.
The Spokesman quoted Dr. Scott Lindquist, Washington State Epidemiologist: “This is a drug that is not available to the general public. It is released on limited use and really was developed for the Ebola crisis. We do know that the manufacturer of this product is trying to work with China to provide this overseas.”
The article states that, “The World Health Organization declared the outbreak a public health emergency on Thursday (January 30).”
Toward the end of the article, one paragraph signals the CDC’s threat awareness of the virus at the time:
“While health officials stress that the likelihood of the novel coronavirus spreading in the U.S. and Washington is relatively low, anyone who has traveled from Wuhan, China should monitor their symptoms and contact their health care provider if they experience fever, cough or shortness of breath. Symptoms can present themselves in as few as two days or as long as two weeks after exposure, according to the CDC. Risk to the general public is still low, however.”
Compare the CDC’s threat assessment concerning the “novel coronavirus” to what Spokane County Health Officer Dr. Bob Lutz said in a May 7 on-line interview with the Spokesman-Review‘s healthcare reporter who wrote the piece quoted above. The topic was the current situation and the future with regard to the pandemic in Spokane and the region.
Race to mass produce and distribute Remdesivir was well underway in China
Lutz: (9:18) ”We were very ill prepared at the federal level, which, again, has really hampered us at the state level, and therefore at the local level to really proceed and to really address the pandemic in a way that we really could have and or should have.”
Reporter: ”…when did you really start reading about Covid-19 in other parts of the world and start to get concerned, and I’m curious if you started sounding alarms in our health district here and started preparing here, when did that thought process begin with you and started to affect your work?”
Lutz: (10:05) “The first awareness we had in the United States was soon, you know, late December – early January, and I think to Department of Health’s credit, as you know, was it in in the media a week ago, a week and a half ago, they noted that they had essentially been monitoring Covid-19 for over 100 days. We did not have formal recognition of monitoring, but with that said, anybody who was in public health following infectious disease, epidemiology, health officers, we were well aware of the fact that an epidemic which was certainly in the making in China was, without doubt, going to move to the United States. And as it did, we were quickly monitoring it. So I think, that to our credit, we actually did have an incident command structure, we had that incident command set up in, I wanna say, late January – early February, and we were meeting…and then, obviously, when the very first case developed in Washington State, that really raised everybody’s awareness. So, we saw it coming. We were very much concerned about it. Were we prepared? Internally, we had done enough preparation, we had plans in place…(11:35) But overall I would say that it’s been challenging because the preparation, really not so much locally, and not so much at the state level, but preparedness was really not to the degree that it should have been.”
Lutz clearly believes the big federal health agencies downplayed the threat.
Much of the U.S. media blames President Trump for a perceived lack of pandemic preparedness. But, the primary responsibility for preparing to deal with national diseases is assigned to the senior leadership of the CDC and the NIH. That includes Dr. Anthony Fauci.
Meanwhile, the race to mass produce and distribute Remdesivir was well underway in China.
Labs in China compete to corner the Remdesivir market
February 17, the Post stated that, “China has begun enrolling Covid-19 patients into a clinical trial of the antiviral, which was developed by the pharmaceutical company Gilead.”
February 6: “Wuhan Institute of Virology Applies for a Patent on Gilead’s Remdesivir”
“The Wuhan Institute of Virology announced on February 4, 2020 that they applied for a Chinese patent on Gilead’s Remdesivir for treating the novel coronavirus (2019-nCoV) that originated in Wuhan in late 2019. The Chinese patent application was filed on January 21, 2020 and the Institute plans to file internationally via the Patent Cooperation Treaty.”
February 12: “Coronavirus: China’s BrightGene Manufactures APIs of Gilead’s Remdesivir”
“A publicly traded Chinese drug developer, BrightGene Bio-Medical Technology Co., said today it has successfully manufactured the active pharmaceutical ingredients (APIs) of remdesivir (GS-5734), the Gilead Science antiviral candidate being tested in China human clinical trials as a treatment for the 2019-nCoV novel coronavirus.”
“‘[BrightGene] actively responded to the national call to fight the new coronavirus (2019-nCoV) epidemic, and recently successfully developed and synthesized the technology and preparations for the drug synthesis of [remdesivir] technology,’ the company stated today.”
“‘The company successfully imitated the development and production of [remdesivir] APIs by virtue of its technical accumulation in the development of high-end APIs and special injections,’ BrightGene added in its statement, issued through the Shanghai Stock Exchange. ‘The company has produced [remdesivir] bulk drugs, and the batch production of Remdesivir preparations is in progress.’”
“BrightGene acknowledged that its marketing of remdesivir ‘still needs to be authorized’ by Gilead, adding, ‘There are many uncertainties in this process, such as drug approval.’ BrightGene did not discuss in its statement what if any efforts the company has undertaken to pursue authorization from Gilead for the imitation product: ‘If the product can be approved for marketing, it will be supplied to relevant patients mainly through donations during the epidemic.’”
“Last week, researchers at China’s Wuhan Institute of Technology applied for a Chinese patent for the use of Gilead Sciences antiviral candidate remdesivir as a treatment for coronavirus, potentially in combination with chloroquine.”
Several China labs rushed to field-test Remdesivir
Meanwhile, as several China labs rushed to field-test Remdesivir as mitigating the effects of a virus that came out of one of their facilities – Wuhan Institute of Technology – let’s review Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, interview with USA TODAY’s Editorial Board on Monday, February 17:
“The U.S. Centers for Disease Control and Prevention will be testing for the coronavirus in people in five major cities who show up at clinics with flu-like symptoms but who test negative for the seasonal varieties. If that testing shows the virus has slipped into the country in places federal officials don’t know about, ‘we’ve got a problem,’ Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told USA TODAY’s Editorial Board Monday.”
“Short of that, Fauci says skip the masks unless you are contagious, don’t worry about catching anything from Chinese products and certainly don’t avoid Chinese people or restaurants…Fauci doesn’t want people to worry about coronavirus, the danger of which is ‘just minuscule.’ But he does want them to take precautions against the ‘influenza outbreak, which is having its second wave.”
“‘We have more kids dying of flu this year at this time than in the last decade or more,’ he said. ‘At the same time people are worrying about going to a Chinese restaurant. The threat is (we have) a pretty bad influenza season, particularly dangerous for our children.’”
SARS-CoV-2 is on the verge of an outbreak in the U.S. and Fauci is more focused on a possible bad flu season. Dr. Lutz in Eastern Washington was ahead of him.
On January 26, Fauci told “The Cats Roundtable” on 970 AM-N.Y. that: “It (Covid-19) isn’t something the American public needs to worry about or be frightened about, because we have ways of preparing and screening people coming in [from China].” In short, “We got this.”
Here’s the status of SARS-CoV-2 at the end of January, and into early February:
While the leading spokesperson for the federal government’s medical establishment, Dr. Fauci, is preaching a passive approach to a disease that the CDC knows has already entered the country in Washington State, Chinese labs are running full speed to produce Gilead’s Remdesivir in an effort to (1) service an undisclosed medical need in China and/or (2) corner the market before the West suffers the full impact of a disease that likely came out of one of their labs.
Next: The Remdesivir vs. Hydroxychloroquine debate heats up, amidst censoring from YouTube. And, the initial focus on lab science melds with political science.
Since November 2007, Lee Cary has written hundreds of articles for several websites including the American Thinker, and Breitbart’s Big Journalism and Big Government (as “Archy Cary”). and the Canada Free Press. Cary’s work was quoted on national television (Sean Hannity) and on nationally syndicated radio (Rush Limbaugh, Mark Levin). His articles have posted on the aggregate sites Drudge Report, Whatfinger, Lucianne, Free Republic, and Real Clear Politics. He holds a Doctorate in Theology from Garrett Theological Seminary in Evanston, IL, is a veteran of the US Army Military Intelligence in Vietnam, and lives in Texas.
Pursuant to Title 17 U.S.C. 107, other copyrighted work is provided for educational purposes, research, critical comment, or debate without profit or payment. If you wish to use copyrighted material from this site for your own purposes beyond the ‘fair use’ exception, you must obtain permission from the copyright owner. Views are those of authors and not necessarily those of Canada Free Press. Content is Copyright 1997-2020 the individual authors. Site Copyright 1997-2020 Canada Free Press.Com